U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07026968) titled 'A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes' on June 10.

Brief Summary: This study is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial to evaluate efficacy and safety of the triple combination therapy of prusogliptin, dapagliflozin and metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone.

Study Start Date: June 17

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose)...